Moderna will seek FDA emergency use authorization for its vaccine in kids under 6
ABC News
Moderna says it plans to seek emergency use authorization from the U.S. Food and Drug Administration for its COVID-19 vaccine in children under age 6.
Moderna said it plans to seek emergency use authorization from the U.S. Food and Drug Administration for its COVID-19 vaccine in children under age 6.
The company released clinical trial data Wednesday showing neutralizing antibody levels were similar to those seen in adults.
The vaccine in children is a two-dose, 25-microgram shot, about a quarter of the dose used for adults.
During the omicron surge, there were enough children infected in the clinical trial to estimate two doses of the vaccine were 44% effective against any COVID-19 infection, including asymptomatic and mild infections, for children aged 6 months to 2 years, Moderna said. The vaccine was also 38% effective among kids aged 2 to 6.
